Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
21/07/2020
TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
14/07/2020
TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
10/06/2020
TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
10/06/2020
TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
10/06/2020
TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
10/06/2020
TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
29/05/2020
TA379: Nintedanib for treating idiopathic pulmonary fibrosis
29/05/2020
TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
29/05/2020
TA356: Ruxolitinib for treating polycythaemia vera (terminated appraisal)
29/05/2020
TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
22/05/2020
TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
22/05/2020
TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
22/05/2020
TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
18/05/2020
TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
18/05/2020
TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
18/05/2020
TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
18/05/2020
TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
18/05/2020
TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
18/05/2020
TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
18/05/2020
TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
6
7
8
9
10
11
12
13
14
15
16
Follow AWTTC: